TATAA Biocenter

The companies said their partnership will result in a complete solution for biomarker discovery, optimization, and validation on a number of platforms.

Tataa will distribute the single-cell whole-genome amplification products in Sweden, Norway, Germany, Austria, Slovakia, and the Czech Republic.

Mo Bio Laboratories has launched the BiOstic FFPE Tissue RNA Isolation Kit.

TATAA Biocenter said this week that its service offering will now include high-throughput gene expression profiling with Ingenuity iReport, Ingenuity Systems’ web-based tool for analyzing gene expression data from RNA sequencing, microarray, and real-time PCR experiments.

TATAA Biocenter said today that it has begun using Ingenuity Systems' iReport software in high-throughput gene expression profiling workflows.

Japan's Toray Industries has taken a step forward in its efforts to sell its microarray platform in the European market.

NEW YORK (GenomeWeb News) – Tataa Biocenter today announced a deal to distribute Polyclone Bioservices' ePrime desktop application.
Tataa will also introduce the qPCR primer and probe design application in its qPCR courses as part of the deal.

NEW YORK (GenomeWeb News) – ZyGem today said it has entered into a non-exclusive distribution deal with Tataa Biocenter.
The deal is for the distribution of ZyGem's DNA and RNA extraction products in Sweden and other selected countries. Other details were not disclosed.

This story has been updated from a previous version to include information about the agreement between TATAA Biocenter and Roche.

TATAA will sell ArcticZymes' heat-labile enzymes for use in contamination control through its sales channels; and will integrate ArcticZymes' products into its range of courses.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.